Helixmith Co., Ltd.
Records under this name other than the patents Helixmith Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 16 patents it holds.
Showing 1 to 6 of 6 · Back to Helixmith Co., Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,219,667 | Method for treating peripheral vascular disease using hepatocyte growth factor and stromal cell derived factor 1A Lapsed on the fee record Ended Jan 11, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jan 11, 2026 | From the USPTO record |
| US 7,279,568 | Highly efficient eukaryotic expression vector comprising an exogenous transcription regulatory element Term ended Term ended Jan 18, 2025 · From the USPTO record | Term ended | Term ended Jan 18, 2025 | From the USPTO record |
| US 7,838,505 | Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor Term ended Term ended Dec 27, 2023 · From the USPTO record | Term ended | Term ended Dec 27, 2023 | From the USPTO record |
| US 8,338,385 | Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor Term ended Term ended Mar 24, 2023 · From the USPTO record | Term ended | Term ended Mar 24, 2023 | From the USPTO record |
| US RE48,404 | Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor Term ended Ended no later than Mar 20, 2023 · From the USPTO record | Term ended | Ended no later than Mar 20, 2023 | From the USPTO record |
| US 7,745,174 | Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor Surrendered on reissue Surrendered on reissue Jan 26, 2021 · From the USPTO record | Surrendered on reissue | Surrendered on reissue Jan 26, 2021 | From the USPTO record |